# Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma

> **NCT07707973** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin First Central Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Glioma, Malignant

## Interventions

- **DRUG:** nimotuzumab
- **DRUG:** Temozolomide
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT07707973
- **Lead sponsor:** Tianjin First Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-03
- **Primary completion:** 2028-01-03
- **Final completion:** 2029-06-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07707973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07707973, "Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07707973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*